Position in LYEL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$824,084
-$440,389 QoQ
Shares Held
41,081
0.0% QoQ
Ownership
0.176%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Ikarian Capital, LLC holds $659,799,686 across 106 Biotechnology names. LYEL ranks #71 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TERN |
Terns Pharmaceuticals, Inc.
|
1,456,378 | $76,780,248 | |
| 2 | KOD |
Kodiak Sciences Inc.
|
1,265,795 | $48,252,105 | |
| 3 | ALMS |
Alumis Inc.
|
1,213,548 | $26,734,462 | |
| 4 | PCVX |
Vaxcyte, Inc.
|
428,682 | $24,910,711 | |
| 5 | PRAX |
Praxis Precision Medicines, Inc.
|
71,581 | $23,062,682 | |
| 6 | RLMD |
Relmada Therapeutics, Inc.
|
2,688,359 | $18,710,978 | |
| 7 | CYTK |
Cytokinetics Inc
|
283,572 | $18,690,230 | |
| 8 | TENX |
Tenax Therapeutics, Inc.
|
1,017,600 | $16,271,424 |
All Filings in LYEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $824,084 | 41,081 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,264,473 | 41,081 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $711,295 | 43,799 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $387,183 | 43,799 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||